United States - English - NLM (National Library of Medicine)

cipla usa inc. - escitalopram oxalate (unii: 5u85dbw7lo) (escitalopram - unii:4o4s742any) - escitalopram 5 mg - escitalopram is indicated for the treatment of: - major depressive disorder (mdd) in adults and pediatric patients 12 years of age and older. - generalized anxiety disorder (gad) in adults and pediatric patients 7 years of age and older. escitalopram is contraindicated in patients: - taking maois with escitalopram or within 14 days of stopping treatment with escitalopram because of an increased risk of serotonin syndrome. the use of escitalopram within 14 days of stopping an maoi intended to treat psychiatric disorders is also contraindicated [see dosage and administration (2.7) and warnings and precautions (5.2)] . starting escitalopram in a patient who is being treated with maois such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome [see dosage and administration (2.6) and warnings and precautions (5.2)] . - taking pimozide [see drug interactions (7)] . - with a hypersensitivity to escitalopram or citalopram or any of the inactive ingredie

Australia - English - Department of Health (Therapeutic Goods Administration)

aurobindo pharma australia pty ltd - citalopram hydrobromide -

Australia - English - Department of Health (Therapeutic Goods Administration)

aurobindo pharma australia pty ltd - citalopram hydrobromide -

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - citalopram hydrobromide, quantity: 12.49 mg (equivalent: citalopram, qty 10 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; lactose monohydrate; maize starch; copovidone; microcrystalline cellulose; magnesium stearate; titanium dioxide; hypromellose; macrogol 400 - treatment of major depression

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - citalopram hydrobromide, quantity: 24.99 mg (equivalent: citalopram, qty 20 mg) - tablet, film coated - excipient ingredients: purified water; macrogol 400; microcrystalline cellulose; purified talc; croscarmellose sodium; lactose monohydrate; hypromellose; titanium dioxide; magnesium stearate; maize starch; pregelatinised maize starch - treatment of major depression

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - citalopram hydrobromide, quantity: 49.98 mg (equivalent: citalopram, qty 40 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; magnesium stearate; hypromellose; microcrystalline cellulose; purified talc; pregelatinised maize starch; macrogol 400; lactose monohydrate; purified water; maize starch; titanium dioxide - treatment of major depression

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - citalopram hydrobromide, quantity: 49.98 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; magnesium stearate; lactose monohydrate; macrogol 400; microcrystalline cellulose; hypromellose; purified talc; titanium dioxide; purified water; maize starch; pregelatinised maize starch - treatment of major depression

United States - English - NLM (National Library of Medicine)

st. mary's medical park pharmacy - escitalopram oxalate (unii: 5u85dbw7lo) (escitalopram - unii:4o4s742any) - escitalopram 20 mg - escitalopram tablets, usp are indicated for the acute and maintenance treatment of major depressive disorder in adults and in adolescents 12 to 17 years of age [ see clinical studies ( 14.1) ]. a major depressive episode (dsm-iv) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least five of the following nine symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt or suicidal ideation. escitalopram tablets,usp are indicated for the acute treatment of generalized anxiety disorder (gad) in adults [ see clinical studies ( 14.2) ].  generalized anxiety disorder (dsm-iv) is characterized by excessive anxiety and worry (apprehensive expectation) that i

United States - English - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - escitalopram oxalate (unii: 5u85dbw7lo) (escitalopram - unii:4o4s742any) - escitalopram 10 mg - escitalopram tablets, usp are indicated for the acute and maintenance treatment of major depressive disorder in adults and in adolescents 12 to 17 years of age [see clinical studies (14.1)].   a major depressive episode (dsm-iv) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least five of the following nine symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt or suicidal ideation. escitalopram tablets, usp are indicated for the acute treatment of generalized anxiety disorder (gad) in adults [see clinical studies (14.2)].   generalized anxiety disorder (dsm-iv) is characterized by excessive anxiety and worry (apprehensive expectation) that is persist

United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals, inc. - escitalopram oxalate (unii: 5u85dbw7lo) (escitalopram - unii:4o4s742any) - escitalopram 10 mg - escitalopram tablets are indicated for the acute and maintenance treatment of major depressive disorder in adults and in adolescents 12 to 17 years of age [see clinical studies (14.1)] . a major depressive episode (dsm-iv) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least five of the following nine symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt or suicidal ideation. escitalopram tablets are indicated for the acute treatment of generalized anxiety disorder (gad) in adults [see clinical studies (14.2)] . generalized anxiety disorder (dsm-iv) is characterized by excessive anxiety and worry (apprehensive expectation) that is persistent